Prospective single-blinded single-center randomized controlled trial of Prep Kit-C and Moviprep: Does underlying inflammatory bowel disease impact tolerability and efficacy?

doi:10.3748/wjg.v27.i11.1090

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4750)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-2) series.

Item

Count

PDF

357

WORD

139

HTML

2397

Figures (1-4)

264

Tables (1-2)

227

Sum=3384

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

449

Download

917

Sum=1366

Mar 21, 2021 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastroenterol. Mar 21, 2021; 27(11): 1090-1100
Published online Mar 21, 2021. doi: 10.3748/wjg.v27.i11.1090

Table 1 Baseline characteristics

	IBD cohort (n = 125)			Non-IBD cohort (n = 213)			P value
mean age +/- SD (yr)	40.3 ± 14.7			50.3 ± 13.4			0.65
	Prep Kit -C	Moviprep	P value	Prep Kit -C	Moviprep	P value
mean ± SD, age (yr)	39.7 ± 14.27	40.9 ± 15.1	0.65	52.98 ± 12.97	53.65 ± 13.98	0.72
Male (n)	35	30	0.13	39	47	0.93

SD: Standard deviation; IBD: Inflammatory bowel disease.

Citation: Mohsen W, Williams AJ, Wark G, Sechi A, Koo JH, Xuan W, Bassan M, Ng W, Connor S. Prospective single-blinded single-center randomized controlled trial of Prep Kit-C and Moviprep: Does underlying inflammatory bowel disease impact tolerability and efficacy? World J Gastroenterol 2021; 27(11): 1090-1100
URL: https://www.wjgnet.com/1007-9327/full/v27/i11/1090.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i11.1090